- Home
- GHI vs BMEA Comparison
GHI vs BMEA Comparison
Compare GHI & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHI
- BMEA
- Stock Information
- Founded
- GHI 1998
- BMEA 2017
- Country
- GHI United States
- BMEA United States
- Employees
- GHI N/A
- BMEA N/A
- Industry
- GHI Finance: Consumer Services
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- GHI Finance
- BMEA Health Care
- Exchange
- GHI Nasdaq
- BMEA Nasdaq
- Market Cap
- GHI 287.2M
- BMEA 275.6M
- IPO Year
- GHI N/A
- BMEA 2021
- Fundamental
- Price
- GHI $11.44
- BMEA $6.53
- Analyst Decision
- GHI Strong Buy
- BMEA Buy
- Analyst Count
- GHI 4
- BMEA 13
- Target Price
- GHI $17.50
- BMEA $37.25
- AVG Volume (30 Days)
- GHI 111.8K
- BMEA 817.8K
- Earning Date
- GHI 11-06-2024
- BMEA 10-29-2024
- Dividend Yield
- GHI 12.96%
- BMEA N/A
- EPS Growth
- GHI N/A
- BMEA N/A
- EPS
- GHI 0.61
- BMEA N/A
- Revenue
- GHI $34,307,528.00
- BMEA N/A
- Revenue This Year
- GHI N/A
- BMEA N/A
- Revenue Next Year
- GHI $5.53
- BMEA N/A
- P/E Ratio
- GHI $18.62
- BMEA N/A
- Revenue Growth
- GHI 1.47
- BMEA N/A
- 52 Week Low
- GHI $10.92
- BMEA $3.61
- 52 Week High
- GHI $17.48
- BMEA $22.74
- Technical
- Relative Strength Index (RSI)
- GHI 34.67
- BMEA 23.64
- Support Level
- GHI $10.92
- BMEA $8.60
- Resistance Level
- GHI $11.55
- BMEA $9.34
- Average True Range (ATR)
- GHI 0.45
- BMEA 0.79
- MACD
- GHI -0.06
- BMEA -0.40
- Stochastic Oscillator
- GHI 25.00
- BMEA 0.82
About GHI Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.